Guardian Pharmacy Services, Inc. is a pharmacy services company providing technology-enabled medication management for long-term care facilities. The company serves residents in assisted living facilities, behavioral health facilities, group homes, and skilled nursing facilities across the United States. Its services include robotic dispensing, compliance packaging, electronic medication administration record integration, caregiver training, and mock audits. Guardian utilizes a local management business model where individual pharmacies operate with support from a national corporate team. The company was founded in 2004 and serves clients through a network of pharmacies that manage prescription lifecycles to improve drug adherence and reduce healthcare costs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Distribution Homepage guardianpharmacy.com
Sector Healthcare IR page investors.guardianpharmacy.com/overview/default.aspx
Tags
long-term care pharmacy, medication management, assisted living services, behavioral health pharmacy, compliance packaging, robotic dispensing, caregiver training, drug regimen adherence, health plan payor services, local management model, GuardianShield
Press page —

Metrics

Valuation  
Market cap $ 3.222B
Market cap (USD) $ 3.222B
P/E 42.72
PEG 3.69
P/BV 11.52
P/S 2.21
P/OCF 28.25
P/FCF 37.10
Dividend yield 0.06%
Turnover / mcap —
Returns  
ROE 26.8%
ROI 31.5%
ROIC 31.1%
Profit margin 3.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 11.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 1.449B 1.228B 1.046B 908.909M 792.072M 0
Net profit 49.219M -110.047M 23.902M 35.421M 16.314M 0
Free cash flow 86.839M 43.25M 56.263M 31.752M 49.216M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 30.09 20.26 — — — —
Price performance 12m 0.49 — — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 77.3M 97.2M 102M
↳ YoY growth +25.7% +4.6%
Borrowings, non-current (USD) — 19M 0.00 —
Lease liabilities (USD) — 29M 37.3M 44.7M
Cash and deposits (USD) 607,000 752,000 4.66M 65.6M
Intangible assets (USD) — 12M 14.9M 18.5M
Right-of-use assets (USD) — 28.1M 29.1M 34.6M
Net debt (borrowings + leases - cash) (USD) — 47.3M 32.7M —
Cash flow detail
Operating cash flow (USD) — 70.8M 58M 100M
Purchases of property, plant and equipment (USD) — -985,000 -14.7M -13.4M
Change in receivables (cash effect) (USD) — -14.3M -25.5M -8.55M
Change in inventories (cash effect) (USD) — 4.43M -1.15M -877,000
Change in payables (cash effect) (USD) — 6.3M 13.2M 16.4M
Share buybacks (cash effect) (USD) — — -55.2M —
Interest paid (cash effect) (USD) — -2.78M -3.12M -650,000
Income taxes paid (cash effect) (USD) — — 0.00 -21.5M
Share-based compensation (USD) — -6.09M 131M 13.9M
Operating cash flow before change in receivables (USD) — 85.1M 83.4M 109M
Free cash flow (OCF - PPE - intangibles) (USD) — 69.8M 43.3M 86.8M
Income detail
Provision for credit losses (USD) — 5.07M 6.37M 4.58M
Credit cost ratio (credit losses / average receivables) (%) — — 7.3% 4.6%
Reported Nov 12, 2024 Mar 26, 2025 Mar 11, 2026 Mar 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

ATLANTA--(BUSINESS WIRE)-- Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the third quarter ended September 30, 2026. The Company also raised its full-year guidance.

Third Quarter Financial Results

  • Residents served ended the quarter at approximately 218,000, up 7% year-over-year.
  • Reported Revenue of $371.1 million, inclusive of pricing decreases as a result of the IRA, down 2% year-over-year.
  • Net Income of $19.1 million, compared to $9.6 million in the prior-year period.
  • Adjusted EBITDA of $33.9 million, up 24% year-over-year.
  • Diluted EPS of $0.29 for the quarter, with Adjusted EPS of $0.33. 1
  • Cash and cash equivalents totaled $119.7 million at quarter-end, with no long-term debt outstanding under our credit facility.

CEO Commentary

"We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would have been up high single digits compared to the third quarter of 2025, mostly driven by organic growth,” said Fred Burke, President and Chief Executive Officer. "Our margin improvement demonstrates the scalability of Guardian's operating model, as well as the progress we are making in driving profitability and leverage across our growing resident base. This performance, together with our positive outlook for the remainder of the year, supports our decision to raise full-year guidance.”

Burke added, “With favorable industry fundamentals, a substantial runway for growth, and a liquid balance sheet, we believe Guardian is well positioned to generate durable growth and attractive long-term returns for shareholders."

FY 2026 Outlook – Updating Guidance

The guidance below excludes any future acquisitions.

Updated Guidance Previous Guidance
Revenue $1.44 billion -$1.46 billion $1.43 billion - $1.45 billion
Adjusted EBITDA $136 million - $138 million $129 million - $131 million

M&A and Greenfields

Guardian continued to advance its growth strategy during the quarter in both new and adjacent markets.

In July, Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy serving Virginia's Shenandoah Valley region. This pharmacy has an established reputation for high-quality service and care, and its integration is progressing as planned.

Guardian also completed the acquisition of certain assets of Nautilus, a pharmacy services provider that previously served assisted living communities across 14 states through a centralized mail-order model. Guardian successfully transitioned the acquired resident base to 18 existing pharmacies within Guardian’s network, providing these communities access to Guardian's locally managed, high-touch pharmacy services. The transaction offers an attractive opportunity to leverage existing infrastructure and operating capacity to generate incremental earnings with limited additional investment.

Subsequent to quarter-end, we added a small pharmacy in Sioux City, Iowa. Collectively, with our existing pharmacy in that area, it gives us a more significant presence in the Northwest part of the state.

Earlier this week, Guardian completed the acquisition of Van's Institutional Pharmacy, a well-established long-term care pharmacy serving communities across western Tennessee and Kentucky. With a history spanning more than 50 years, Van's brings a strong reputation for quality care and service. The acquisition increases Guardian's Tennessee footprint to five pharmacy locations.

Guardian also made progress on its greenfield development initiatives. Its previously announced pharmacy in Lexington, Kentucky is now operational. We are also advancing plans to expand our presence in Texas and Alabama, with new locations in Houston and Huntsville, respectively. Each location will represent our second pharmacy in those states.

To support its expanding pharmacy network, Guardian continues to strengthen regional leadership and operational coordination, with a focus on sharing best practices, enhancing customer service, and capturing efficiencies while preserving the locally managed operating model that distinguishes the Company.

____________________________
1 Diluted EPS and Adjusted EPS include dilutive shares related to restricted stock units. See reconciliation of Adjusted EPS to Diluted EPS, the most directly comparable GAAP measure, below.

Share Structure and Insider Ownership

On September 27, 2026, approximately 13.5 million shares of Guardian's Class B common stock converted into Class A common stock, completing the two-year share conversion process that commenced with the Company's September 2024 corporate reorganization effected in connection with its initial public offering (“IPO”).

Prior to the conversion, Guardian's founders, executive officers, and certain other employees entered into lock-up agreements covering approximately 29.9 million shares, representing approximately 80% of the Class A shares held by founders, executive officers, and other pre-IPO employee shareholders. These shares remain subject to lock-up restrictions through September 14, 2027, subject to limited exceptions.

The substantial continued ownership by Guardian's founders, management team, and employees reinforces their long-term alignment with Guardian’s public shareholders.

Conference Call Details

Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing +1 (833) 461-5787 for participants located in the United States and Canada, or +1 (585) 542-9983 for international participants, and referencing conference ID “969 326 559” A webcast replay will be available shortly after the call’s completion at https://investors.guardianpharmacy.com

About Guardian Pharmacy Services

Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally‑based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 63 licensed pharmacies, 57 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 218,000 residents (as of September 30, 2026).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and are forward-looking. These statements are often, but not always, made through the use of words such as “aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “should,” “will,” “would,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business and growth strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; our ability to identify, complete and successfully integrate acquisitions; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees, business, supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by capping the prices for certain drugs and limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; and the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors” section contained in our most recent Annual Report on Form 10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.

Additional Information

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the SEC’s website at www.sec.gov .

Use of Non-GAAP Financial Measures

To supplement the results presented in our consolidated financial statements in accordance with GAAP, we also present Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS, which are financial measures not based on any standardized methodology prescribed by GAAP.

We define Adjusted EBITDA as net income before interest expense (income), income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.

We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, and the income tax impact of the adjustments.

We define Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A common stock and Class B common stock.

Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS may not be the same as, or comparable to, similarly titled measures used by other companies.

We use Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.

There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS rather than the most directly comparable GAAP financial measure, including:

  • Adjusted EBITDA does not reflect interest and income tax payments that represent a reduction in cash available to us;
  • Depreciation and amortization are non-cash charges and the assets being depreciated may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
  • Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not reflect changes in, or cash requirements for, our working capital needs;
  • Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not consider the impact of share-based compensation; and
  • Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS exclude the impact of certain legal and regulatory items, and payor-reimbursement matters which can affect our current and future cash requirements.

Because of these limitations, Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS alongside other financial measures, including net income, diluted EPS, and our other financial results presented in accordance with GAAP.

A reconciliation of Adjusted EBITDA to net income and of Adjusted Net Income to Net Income Attributable to Guardian Pharmacy Services, Inc., the most directly comparable GAAP financial measures, are set forth below.

Guardian has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share amounts) December 31, 2025 September 30, 2026
Assets
Current assets:
Cash and cash equivalents $ 65,619 $ 119,655
Accounts receivable, net 101,614 107,677
Inventories 43,359 57,051
Other current assets 11,042 10,434
Total current assets 221,634 294,817
Property and equipment, net 55,522 57,424
Intangible assets, net 18,475 20,842
Goodwill 79,743 81,954
Operating lease right-of-use assets 34,649 32,774
Deferred tax assets 2,199 2,618
Other assets 436 1,347
Total assets $ 412,658 $ 491,776
Liabilities and equity
Current liabilities:
Accounts payable $ 116,206 $ 126,307
Accrued compensation 15,048 19,874
Operating leases, current portion 7,150 7,632
Other current liabilities 22,299 25,276
Total current liabilities 160,703 179,089
Operating leases, net of current portion 29,992 27,962
Other liabilities 4,039 5,005
Total liabilities $ 194,734 $ 212,056
Commitments and contingencies (see Note 6)
Equity:
Class A common stock - 700,000,000 shares authorized, par value $0.001; 36,253,744 and 63,320,300 shares issued and outstanding as of December 31, 2025 and September 30, 2026, respectively 36 63
Class B common stock - 100,000,000 shares authorized, par value $0.001; 27,066,890 and 22,004 shares issued and outstanding as of December 31, 2025 and September 30, 2026, respectively 27 —
Additional paid-in capital 139,353 146,982
Retained earnings 66,343 120,190
Non-controlling interests 12,165 12,485
Total equity 217,924 279,720
Total liabilities and equity $ 412,658 $ 491,776
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended September 30, Nine Months Ended September 30,
(In thousands, except share and per share amounts) 2025 2026 2025 2026
Revenues $ 377,427 $ 371,070 $ 1,051,069 $ 1,059,433
Cost of goods sold 302,706 285,847 843,853 817,857
Gross profit 74,721 85,223 207,216 241,576
Selling, general, and administrative expenses 58,367 60,160 165,277 178,194
Operating income 16,354 25,063 41,939 63,382
Other expenses (income):
Interest expense 160 177 502 485
Other expense (income), net (437 ) (1,091 ) (887 ) (11,165 )
Total other expenses (income) (277 ) (914 ) (385 ) (10,680 )
Income before income taxes 16,631 25,977 42,324 74,062
Provision for income taxes 7,038 6,857 14,631 19,277
Net income 9,593 19,120 27,693 54,785
Less net income (loss) attributable to non-controlling interests (225 ) 440 (603 ) 938
Net income attributable to Guardian Pharmacy Services, Inc. $ 9,818 $ 18,680 $ 28,296 $ 53,847
Net income per share of Class A and Class B common stock
Basic $ 0.16 $ 0.29 $ 0.46 $ 0.85
Diluted $ 0.15 $ 0.29 $ 0.45 $ 0.84
Weighted-average Class A and Class B common shares outstanding
Basic 62,124 63,343 62,071 63,330
Diluted 63,432 63,916 63,180 63,813
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Nine Months Ended September 30,
(In thousands) 2025 2026
Operating activities
Net income $ 27,693 $ 54,785
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 16,594 17,716
Share-based compensation expense 12,770 7,528
Provision for losses on accounts receivable 3,110 4,116
Change in deferred tax asset 710 (419 )
Other 585 (122 )
Changes in operating assets and liabilities:
Accounts receivable (11,593 ) (9,771 )
Inventories (5,669 ) (13,081 )
Other current assets 858 (219 )
Accounts payable 21,148 9,555
Accrued compensation 1,514 4,826
Other operating liabilities (2,065 ) 4,543
Net cash provided by operating activities 65,655 79,457
Investing activities
Purchases of property and equipment (15,318 ) (13,663 )
Payment for business combinations (12,921 ) (2,642 )
Payment for asset acquisition — (4,400 )
Other 724 746
Net cash used in investing activities (27,515 ) (19,959 )
Financing activities
Proceeds from equity offering, net of underwriter fees 29,039 30,276
Repurchase of outstanding Class A common stock (29,039 ) (30,276 )
Payments of equity offering costs (1,594 ) —
Repayment of notes payable (497 ) —
Principal payments on finance lease obligations (3,393 ) (3,214 )
Contingent liability payments related to acquisitions (2,259 ) (1,700 )
Contributions from non-controlling interests 1,619 1,180
Distributions to non-controlling interests (189 ) (1,798 )
Other — 70
Net cash used in financing activities (6,313 ) (5,462 )
Net change in cash and cash equivalents 31,827 54,036
Cash and cash equivalents, beginning of period 4,660 65,619
Cash and cash equivalents, end of period $ 36,487 $ 119,655
Supplemental disclosure of cash flow information
Cash paid during the year for interest $ 510 $ 450
Cash paid during the year for income taxes $ 17,591 $ 20,702
Supplemental disclosure of non-cash investing and financing activities
Purchases of property and equipment through finance leases $ 3,623 $ 3,016
Non-cash equity contributions from non-controlling interests $ 3,609 $ —
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED EPS TO THE MOST DIRECTLY COMPARABLE GAAP FINANCIAL MEASURES
(UNAUDITED)
**Three Months Ended **September 30, **Nine Months Ended **September 30,
(in thousands) 2025 2026 2025 2026
Net income $ 9,593 $ 19,120 $ 27,693 $ 54,785
Add:
Interest expense (income), net (133 ) (813 ) (203 ) (1,733 )
Depreciation and amortization 5,838 5,932 16,594 17,716
Provision for income taxes 7,038 6,857 14,631 19,277
EBITDA $ 22,336 $ 31,096 $ 58,715 $ 90,045
Share-based compensation (1) 4,356 2,735 12,770 7,528
Certain legal & other regulatory matters (2) 435 19 1,057 37
Financing-related and other activities (3) 110 — 1,924 873
Payor-reimbursement matters (4) 38 3 1,193 (5,214 )
Adjusted EBITDA $ 27,275 $ 33,853 $ 75,659 $ 93,269
Net income as a percentage of revenue 2.5 % 5.2 % 2.6 % 5.2 %
Adjusted EBITDA as a percentage of revenue 7.2 % 9.1 % 7.2 % 8.8 %
Net Income attributable to Guardian Pharmacy Services, Inc. $ 9,818 $ 18,680 $ 28,296 $ 53,847
Share-based compensation (1) 4,356 2,735 12,770 7,528
Certain legal & other regulatory matters (2) 435 19 1,057 37
Financing-related and other activities (3) 110 — 1,924 873
Payor-reimbursement matters (4) 38 3 1,193 (5,214 )
Acquisition-related intangible asset amortization (5) 978 893 2,687 2,750
Income tax impact of adjustments (6) (1,759 ) (949 ) (5,854 ) (1,553 )
Certain tax matters related to Corporate Reorganization and IPO (7) 1,725 — 1,725 —
Adjusted net income $ 15,701 $ 21,381 $ 43,798 $ 58,268
Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income per share 63,432 63,916 63,180 63,813
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per share 63,432 63,916 63,180 63,813
Diluted EPS $ 0.15 $ 0.29 $ 0.45 $ 0.84
Adjusted EPS $ 0.25 $ 0.33 $ 0.69 $ 0.91
(1) See Note 8 - Share-based Compensation of the Notes to Unaudited Condensed Consolidated Financial Statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 for further detail on the share-based compensation expense.
(2) Represents non-recurring attorney’s fees, settlement costs and other expenses, and insurance reimbursements related to settlements, associated with certain legal proceedings. The Company excludes such charges and reimbursements, recorded as selling, general, and administrative expenses, when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations.
(3) Represents non-recurring costs associated with various financing-related activities included in the three and nine months ended September 30, 2025 and 2026, and costs to transition to a public company included in the three and nine months ended September 30, 2025.
(4) Represents non-recurring settlements, recorded as other income, proceeds received, recorded as revenue, and legal expenses, recorded as selling, general and administrative expenses, associated with payor reimbursement matters.
Settlements received associated with payor reimbursement matters, recorded as other income, were $0.0 million and $8.5 million during the three and nine months ended September 30, 2026, respectively, and $0.0 million during the three and nine months ended September 30, 2025.
Proceeds received associated with payor reimbursement matters, recorded as revenue, were $0.0 million during the three and nine months ended September 30, 2026, and $1.6 million during the three and nine months ended September 30, 2025.
Legal expenses associated with payor reimbursement matters, recorded as selling, general and administrative expenses, were $0.0 million and $3.2 million during the three and nine months ended September 30, 2026, respectively, and $1.7 million and $2.8 million during the three and nine months ended September 30, 2025, respectively.
On April 21, 2026, the Company executed a mutual release and settlement agreement related to a payor-reimbursement matter. As part of the settlement, the Company received an $8.5 million cash payment, which is recorded in Other expense (income) on the Condensed Consolidated Statement of Operations.
(5) Represents amortization expense associated with the acquisition-related intangible assets, such as customer lists and trademarks.
(6) Represents the income tax impact of non-GAAP adjustments, calculated using the estimated tax rate for the respective non-GAAP adjustment.
(7) Represents non-recurring income tax expense associated with the Corporate Reorganization and IPO. The Company excludes such charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations.

Investor Contact:
Ashley Stockton, Vice President, Investor Relations
[email protected]

Source: Guardian Pharmacy Services, Inc.

View All News

Skip to content

Facebook page opens in new window Linkedin page opens in new window X page opens in new window

Guardian Pharmacy Services

Long-Term Care Pharmacy

Guardian Pharmacy Services

Contact Us

Guardian Pharmacy Services Guardian Pharmacy Services Guardian Pharmacy Services

Facebook page opens in new window Linkedin page opens in new window X page opens in new window

Facebook page opens in new window Linkedin page opens in new window X page opens in new window

Nov32026

News

Guardian Pharmacy Services Acquires Van’s Institutional Pharmacy, Expanding Footprint in Tennessee and Kentucky

Guardian Pharmacy Services has expanded its presence in Tennessee and Kentucky through the acquisition of Van’s Institutional Pharmacy, a long-term care (LTC) pharmacy based in Martin, Tennessee. The addition grows Guardian’s Tennessee operations to five pharmacies in Memphis, Shelbyville, Murfreesboro, Knoxville, and Martin, strengthening its ability to meet increasing demand for LTC pharmacy services across the region.

Founded in 1974, Van’s Institutional Pharmacy serves residents in assisted living, skilled nursing, and behavioral health communities, as well as individuals with intellectual and developmental disabilities, across Tennessee and Kentucky. Co-Presidents Zach Delaney and Emily Haskins will lead day-to-day operations while former President Mike Swaim remains actively involved in the pharmacy as a senior advisor. The pharmacy’s existing leadership and staff will stay in place, and it will continue to operate as Van’s Institutional Pharmacy.

As with Guardian’s other acquisitions, Van’s Institutional Pharmacy will benefit from the company’s unique business model, which combines local pharmacy leadership and decision-making with centralized corporate support. This allows the local team to remain focused on customer service and the specialized needs of the communities and residents they serve, while Guardian’s Corporate Support Team assists with complex behind-the-scenes business functions, including data analytics, HR, IT, payor relations, national sales and more.

For more details about the acquisition, CLICK HERE>

Related Posts

Middle Tennessee Pharmacy Services Promotes Carrie Beth Gregory to Co-President

August 6, 2026

Guardian Pharmacy Services Opens Long-Term Care Pharmacy in Lexington, Kentucky

August 3, 2026

Guardian Pharmacy Services and Wellness Concepts logos.

Guardian Pharmacy Services Expands Virginia Footprint with Acquisition of Wellness Concepts

July 1, 2026

Guardian Pharmacy Services Announces Leadership Transitions

June 23, 2026

Laura Polinsky

Guardian Pharmacy of Jacksonville Promotes Laura Polinsky to President

June 16, 2026

Guardian Pharmacy Services Announces Senior Leadership Promotions to Support Continued Growth and Operational Alignment

May 12, 2026

**Careers

| Locations | Contact Us **

Privacy / Terms HIPAA Privacy Policy Media Contact

Go to Top

Our Spring Sale Has Started

You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/

×

November 2, 2026

ATLANTA--(BUSINESS WIRE)-- Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s largest and most innovative long-term care (LTC) pharmacy services companies, today announced the acquisition of Van’s Institutional Pharmacy, an LTC pharmacy based in Martin, Tenn. The addition grows Guardian’s Tennessee operations to five pharmacies in Memphis, Shelbyville, Murfreesboro, Knoxville, and Martin, strengthening its ability to meet increasing demand for LTC pharmacy services in Tennessee and Kentucky.

Founded in 1974, Van’s Institutional Pharmacy serves residents in assisted living, skilled nursing, and behavioral health communities, as well as individuals with intellectual and developmental disabilities, across Tennessee and Kentucky. Co-Presidents Zach Delaney and Emily Haskins will lead day-to-day operations while former President Mike Swaim remains actively involved in the pharmacy as a senior advisor. The pharmacy’s existing leadership and staff will stay in place, and it will continue to operate as Van’s Institutional Pharmacy.

“With demand for dependable LTC pharmacy partners growing in the region, we’re excited to add Van’s Institutional Pharmacy, which has earned the confidence of LTC communities through decades of reliable, high-touch service and expertise,” said David Brown, senior vice president of the Central Region at Guardian Pharmacy Services. “We look forward to welcoming the Van’s team to the Guardian family and building on that reputation to serve its current customers and meet the needs of new ones.”

As with Guardian’s other acquisitions, Van’s Institutional Pharmacy will benefit from the company’s unique business model, which combines local pharmacy leadership and decision-making with centralized corporate support. This allows the local team to remain focused on customer service and the specialized needs of the communities and residents they serve, while Guardian’s Corporate Support Team assists with complex behind-the-scenes business functions, including data analytics, HR, IT, payor relations, national sales and more.

“For more than 50 years, our family built a successful pharmacy by doing right by our customers and staff,” said Swaim of Van’s Institutional Pharmacy. “Joining Guardian allows our team to stay together and focused on the relationships and service that have defined Van’s, now with the benefit of the expertise and resources of a national LTC pharmacy organization. With this partnership, we can further strengthen the personal service our customers expect and deserve.”

About Guardian Pharmacy Services

Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 61 licensed pharmacies, 54 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 210,000 residents (as of June 30, 2026).

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated growth, future hiring, and expanded service offerings. These statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, including those described in Guardian’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission from time to time, and which are publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com . Actual results may differ materially from those expressed or implied in these statements. Guardian Pharmacy Services undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact:
Andrew Agan, Cookerly PR
404-816-2037
[email protected]

Investor Contact:
Ashley Stockton
Vice President, Investor Relations
[email protected]

Source: Guardian Pharmacy Services, Inc.

View All News

Prompts

Guardian Pharmacy Services, Inc. (ticker GRDN), listed in United States.

Company History

Date Change Detail
Mar 11, 2020 Renamed Guardian Pharmacy, LLC → GUARDIAN PHARMACY SERVICES, INC.

ETFs Holding Guardian Pharmacy Services, Inc.

ETF Weight in ETF Shares Market value As of
SAWS 2.84% 5,622 $ 222.238K Jul 31, 2026
LITL 0.67% 758 $ 38.15K Nov 17, 2026
AFSM 0.22% 6,369 $ 314.82K Nov 16, 2026
VFQY 0.08% 11,555 $ 428.575K Aug 31, 2026
VFMO 0.08% 42,721 $ 1.585M Aug 31, 2026
AVSC 0.08% 52,692 $ 2.605M Nov 16, 2026
VFMF 0.07% 19,253 $ 714.094K Aug 31, 2026
IVSS 0.07% 433 $ 18.13K Jun 30, 2026
PSC 0.06% 30,974 $ 1.297M Jun 30, 2026
RESM 0.05% 41 $ 1,716.67 Jun 30, 2026
DFAS 0.04% 251,456 $ 12.417M Nov 12, 2026
DXUV 0.02% 24,539 $ 1.212M Nov 12, 2026
AVUQ 0.01% 1,068 $ 52.791K Nov 16, 2026
DFSU 0.01% 4,691 $ 231.642K Nov 12, 2026
DCOR 0.01% 49,458 $ 2.442M Nov 12, 2026
DFAC 0.00% 75,687 $ 3.737M Nov 12, 2026
MSSM 0.00% 773 $ 28.671K Aug 31, 2026
DFUS 0.00% 14,857 $ 733.639K Nov 12, 2026
DFAU 0.00% 7,209 $ 355.98K Nov 12, 2026
EBI 0.00% 28 $ 1,038.52 Aug 31, 2026
AVUS 0.00% 11,513 $ 569.088K Nov 16, 2026
AVSU 0.00% 210 $ 10.38K Nov 16, 2026
NTRL 0.00% 5,230 $ 0.00 Nov 16, 2026